Table 2.
Proportion of event of interests on all combinations of the two drugs
| No A, no B | A, no B | No A, B | A and B | |
|---|---|---|---|---|
| Simvastatin(A)-ciclosporin(B) and MYP | 2740/4869677 | 187/65940 | 113/45327 | 25/1342 |
| Methotrexate(A)-diclofenac(B) and BMD | 3732/4874109 | 282/63620 | 57/42612 | 27/1945 |
| Ketoconazole(A)-terfenadine(B) and TdP | 1497/4947013 | 12/11088 | 54/23683 | 7/502 |
| Cisapride(A)-erythromycin(B) and TdP | 1182/4900646 | 271/43497 | 101/37416 | 16/727 |
| Methotrexate(A)-rofecoxib(B) and BMD | 3767/4861514 | 310/63259 | 19/54795 | 2/2718 |
| Fluvastatin(A)-ciclosporin(B) and MYP | 2889/4925704 | 38/9913 | 137/46473 | 1/196 |
| Cisapride(A)-azithromycin(B) and TdP | 1518/5490501 | 293/44322 | 39/40140 | 2/776 |
| Fexofenadine(A)-ketoconazole(B) and TdP | 1540/4956019 | 11/14677 | 19/11544 | 0/46 |
BMD bone marrow depression; MYP myopathy; TdP Torsades de pointes.